Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Mouse (Murine) Antibodies:
anti-Rat (Rattus) Antibodies:
Go to our pre-filtered search.
Human Polyclonal PSMD10 Primary Antibody for WB - ABIN1944780
Ota, Suzuki, Nishikawa, Otsuki, Sugiyama, Irie, Wakamatsu, Hayashi, Sato, Nagai, Kimura, Makita, Sekine, Obayashi, Nishi, Shibahara, Tanaka, Ishii, Yamamoto, Saito, Kawai, Isono, Nakamura, Nagahari et al.: Complete sequencing and characterization of 21,243 full-length human cDNAs. ... in Nature genetics 2003
Show all 2 Pubmed References
Bat Polyclonal PSMD10 Primary Antibody for WB - ABIN611034
Hay, Chao, Kuo, Scheller: Protein interactions regulating vesicle transport between the endoplasmic reticulum and Golgi apparatus in mammalian cells. in Cell 1997
Show all 3 Pubmed References
Gankyrin expression promotes spontaneous cancer and non-cancerous liver diseases. Gankyrin accelerates liver steatosis, cholangitis, fibrosis, and hepatocarcinogenesis with persistent damage and proliferation in hepatocytes.
This study is the first to report gankyrin as a potential link between microRNAs and liver steatosis in zebrafish.
we conclude that FXR (show NR1H4 Antibodies)-Gank-TSPs-Stem cells pathway is a key determinant of liver cancer in animal models and in pediatric liver cancer. Our data provide a strong basis for development of FXR (show NR1H4 Antibodies)-Gank-based therapy for treatment of patients with hepatoblastoma
p28 assists the proteolytic core particle to select a specific conformation of the ATPase (show DNAH8 Antibodies) ring for regulatory particle engagement and is released in a shoehorn-like fashion in the last step of the chaperone-mediated proteasome assembly.
gankyrin regulates HIF-1alpha (show HIF1A Antibodies) protein stability and cyclin D1 (show CCND1 Antibodies) expression, ultimately mediating FSH (show BRD2 Antibodies)-driven ovarian cancer cell proliferation
The positive feedback regulation involving gankyrin and Nrf2 (show GABPA Antibodies) modulates a series of antioxidant enzymes, thereby lowering intracellular ROS (show ROS1 Antibodies) and conferring a steadier intracellular environment, which prevents mitochondrial damage and cell death induced by excessive oxidative stress.
Gankyrin enhanced gastric cancer cell proliferation by regulating cell cycle-related proteins and by activating PI3K (show PIK3CA Antibodies)/AKT (show AKT1 Antibodies) signaling pathway. Gankyrin played an important role in gastric carcinogenesis and could be a potential effective therapeutic target for enhancing chemosensitivity to 5-fluorouracil and cisplatin.
gankyrin is an oncoprotein that can be modified by small molecules in tumor cell lines
Gankyrin overexpression activates mTORC1 signaling and accelerating TSC2 (show TSC2 Antibodies) degradation in colorectal tumor cells.
Gankyrin is an oncoprotein that facilitates the degradation of two key tumor suppressors, namely, Rb and p53 (show TP53 Antibodies). Gankyrin is involved in the regulation of cell signaling pathways, with particular reference to RhoA (show RHOA Antibodies)/ROCK/PTEN (show PTEN Antibodies)/PI3K (show PIK3CA Antibodies)/Akt (show AKT1 Antibodies), beta-catenin (show CTNNB1 Antibodies), IL-6 (show IL6 Antibodies)/STAT3 (show STAT3 Antibodies), and IL-1beta (show IL1B Antibodies)/IRAK-1 (show IRAK1 Antibodies) inflammatory signaling. Review.
Gankyrin-overexpressed non-small cell lung cancer patients had a significantly shorter survival time
Results identified rs111638916 SNP in the PSMD10 3'-UTR (show UTS2R Antibodies) as a risk factor for gastric cancer (GC) and acted as a tumor promoting factor. SNP rs111638916 was also regulated by miR (show MLXIP Antibodies)-505, resulting in its up-regulation in patients with GA and AA genotypes.
the present study clarified, at least partly, mechanisms of vascular tumorigenesis, and suggests that gankyrin might play a physiological role in hypoxic responses besides its roles as an oncoprotein.
FXR (show NR1H4 Antibodies) prevents liver cancer by inhibiting the gankyrin promoter via C/EBPbeta (show CEBPB Antibodies)-HDAC1 (show HDAC1 Antibodies) complexes, leading to subsequent protection of tumor suppressor proteins from degradation.
Gankyrin is a key regulator of Ras-mediated activation of Akt through inhibition of the downstream RhoA/ROCK pathway and thus plays an essential role in Ras-induced tumorigenesis.
Findings suggest that retinoblastoma protein degradation in Lmna (show LMNA Antibodies)-/- cells occurs by gankyrin and MDM2 (show MDM2 Antibodies)-independent mechanisms.
Gankyrin oncoprotein has a role in progression of esophageal squamous cell carcinoma
This gene encodes a subunit of the PA700/19S complex, which is the regulatory component of the 26S proteasome. The 26S proteosome complex is required for ubiquitin-dependent protein degradation. This protein is a non-ATPase subunit that may be involved in protein-protein interactions. Aberrant expression of this gene may paly a role in tumorigenesis. Two transcripts encoding different isoforms have been described. Pseudogenes have been identified on chromosomes 3 and 20.
26S proteasome non-ATPase regulatory subunit 10
, proteasome 26S subunit, non-ATPase, 10
, 26S proteasome regulatory subunit p28
, ankyrin repeat protein
, hepatocellular carcinoma-associated protein p28-II
, proteasome subunit p28
, proteosome (prosome, macropain) 26S subunit, non-ATPase, 10
, proteosome subunit p28
, proteasome 26S non-ATPase subunit 10